Clinical trial
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients…
NCT00372593 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00372593 |
|---|---|
| Title | Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Official title | A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, mitoxantrone hydrochloride |
| Enrollment | 1,070 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2013 |
| Completion | Sep 30, 2020 |
| First posted | Sep 7, 2006 |
| Last update posted | Mar 24, 2021 |
| Countries | Australia, Canada, New Zealand, Puerto Rico, Switzerland, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: